Research Article
Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study
Table 4
Adverse drug reactions for all patients.
| | Complication, (%) | I | II | III | Total | I | II | III | Total | | | Combined group () | Control group () | |
| | Nausea | 16 | 8 | 2 | 26 (83.9) | 9 | 4 | 1 | 17 (54.8) | <0.001 | | Vomiting | 11 | 7 | 1 | 19 (61.3) | 5 | 1 | 0 | 9 (29.0) | <0.001 | | Hemoglobin decrease | 8 | 8 | 2 | 18 (58.1) | 9 | 2 | 0 | 11 (35.5) | 0.002 | | Hypertension | 8 | 7 | 1 | 16 (51.6) | 2 | 1 | 0 | 3 (9.7) | <0.001 | | Leukopenia | 13 | 9 | 3 | 25 (90.3) | 15 | 7 | 2 | 24 (77.4) | 0.013 | | Thrombocytopenia | 4 | 1 | 0 | 5 (16.1) | 5 | 1 | 0 | 6 (19.4) | 0.541 | | Proteinuria | 8 | 3 | 0 | 11 (35.4) | 2 | 1 | 0 | 3 (9.7) | <0.001 | | Diarrhea | 4 | 2 | 0 | 6 (19.3) | 2 | 2 | 0 | 4 (12.9) | 0.218 | | Hand-and-foot syndrome | 6 | 3 | 2 | 11 (35.4) | 5 | 4 | 1 | 10 (32.2) | 0.765 | | Fatigue | 5 | 4 | 0 | 9 (29.0) | 4 | 3 | 0 | 7 (22.6) | 0.301 |
|
|
